4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Sex-Specific Differences in the Association Between Race/Ethnicity and NAFLD Among US Population

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Non-alcoholic fatty liver disease (NAFLD) is spreading worldwide, with a racial/ethnic disparity. We examined the gender role in the racial/ethnic difference in NAFLD in the US population. We analyzed data for 3,292 individuals ≥18 years old from NHANES 2017–2018, a representative sample of the non-institutionalized adult population in the US. Exclusions were subjects with elevated transferrin level, chronic hepatitis B or C, excessive alcohol use, or prescription medications that might cause hepatic steatosis. NAFLD was diagnosed by FibroScan ® using controlled attenuation parameter (CAP) values: S0 <238, S1 = 238–259, S2 = 260–290, S3 >290. Data were analyzed using Chi square and multinomial regression. The overall prevalence of NAFLD was 47.9% [S2 = 16.1%, and S3 = 31.8%]. The prevalence of S3 was highest among Mexican Americans (46%), lowest among Blacks (22.7%), 29.9% in other Hispanics and 32.1% in Whites ( p < 0.05). It was higher among Mexican American males (54.1%) compared to Mexican American females (37.7%) ( p < 0.05). In the adjusted model, Mexican Americans were two times more likely than Whites to have S2 and S3 ( p < 0.05). Only male Mexican Americans had higher odds of S2 and S3 relative to male White ( p < 0.05). Males had higher odds of S3 relative to non-menopausal females ( p < 0.05). There was no difference in the odds of S2 or S3 NAFLD among the menopausal females with or without hormone therapy relative to non-menopausal females ( p > 0.05). While Mexican Americans had the highest prevalence of severe NAFLD relative to the other racial/ethnic groups, only male Mexican Americans, but not females, had higher likelihood of both moderate and severe NAFLD relative to Whites. Interventions that specifically target Mexican American males are needed to increase awareness about NAFLD and its prevention.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: not found
          • Article: not found

          EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

          (2016)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

            Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem of unknown etiology that varies in prevalence among ethnic groups. To identify genetic variants contributing to differences in hepatic fat content, we performed a genome-wide association scan of nonsynonymous sequence variations (n=9,229) in a multiethnic population. An allele in PNPLA3 (rs738409; I148M) was strongly associated with increased hepatic fat levels (P=5.9×10−10) and with hepatic inflammation (P=3.7×10−4). The allele was most common in Hispanics, the group most susceptible to NAFLD; hepatic fat content was > 2-fold higher in PNPLA3-148M homozygotes than in noncarriers. Resequencing revealed another allele associated with lower hepatic fat content in African-Americans, the group at lowest risk of NAFLD. Thus, variation in PNPLA3 contributes to ethnic and inter-individual differences in hepatic fat content and susceptibility to NAFLD.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Non-alcoholic fatty liver disease – A global public health perspective

              As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of NAFLD which can be characterised as non-alcoholic steatohepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death. NAFLD is also associated with extrahepatic manifestations such as chronic kidney disease, cardiovascular disease and sleep apnoea. NAFLD and NASH carry a large economic burden and create poor health-related quality of life. Despite this important burden, we are only beginning to understand its mechanisms of pathogenesis and the contribution of environmental and genetic factors to the risk of developing a progressive course of disease. Research is underway to identify appropriate non-invasive diagnostic methods and effective treatments. Although the risk of liver-related mortality is increased in patients with NAFLD and liver fibrosis stages F3 or F4, the leading cause of death is cardiovascular disease. Given the rapidly growing global burden of NAFLD and NASH, efforts must continue to find accurate non-invasive diagnostic and prognostic biomarkers, to develop effective treatments for individuals with advanced NASH and prevention methods for individuals at high risk of NAFLD and progressive liver disease.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Med (Lausanne)
                Front Med (Lausanne)
                Front. Med.
                Frontiers in Medicine
                Frontiers Media S.A.
                2296-858X
                02 December 2021
                2021
                : 8
                : 795421
                Affiliations
                [1] 1College of Medicine, Charles R Drew University , Los Angeles, CA, United States
                [2] 2Heritage College of Osteopathic Medicine, Ohio University , Athens, OH, United States
                [3] 3University of Florida College of Medicine , Gainesville, FL, United States
                Author notes

                Edited by: Angel Lanas, University of Zaragoza, Spain

                Reviewed by: Zuzana Macek Jilkova, Centre Hospitalier Universitaire de Grenoble, France; Mengfei Liu, Mayo Clinic, United States

                *Correspondence: Magda Shaheen magdashaheen@ 123456cdrewu.edu

                This article was submitted to Gastroenterology, a section of the journal Frontiers in Medicine

                Article
                10.3389/fmed.2021.795421
                8674562
                34926533
                607cb23d-b267-40eb-a692-d42d92c02b7a
                Copyright © 2021 Shaheen, Schrode, Pan, Kermah, Puri, Zarrinpar, Elisha, Najjar and Friedman.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 15 October 2021
                : 08 November 2021
                Page count
                Figures: 3, Tables: 7, Equations: 0, References: 44, Pages: 17, Words: 10432
                Funding
                Funded by: National Institute on Minority Health and Health Disparities, doi 10.13039/100006545;
                Award ID: R01MD012579
                Award ID: S21MD000103
                Award ID: U54MD007598
                Funded by: National Institute on Drug Abuse, doi 10.13039/100000026;
                Award ID: R24DA017298
                Funded by: National Center for Advancing Translational Sciences, doi 10.13039/100006108;
                Award ID: UL1TR000124
                Categories
                Medicine
                Original Research

                sex,non-alcoholic fatty liver disease (nafld),nhanes 2017–2018,race/ethnicity,disparity

                Comments

                Comment on this article